↓ Skip to main content

Double suicide gene therapy using human neural stem cells against glioblastoma: double safety measures

Overview of attention for article published in Journal of Neuro-Oncology, October 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
14 Mendeley
Title
Double suicide gene therapy using human neural stem cells against glioblastoma: double safety measures
Published in
Journal of Neuro-Oncology, October 2013
DOI 10.1007/s11060-013-1264-6
Pubmed ID
Authors

Ji Yeoun Lee, Do-Hun Lee, Hyung A. Kim, Seung-Ah Choi, Hong Jun Lee, Chul-Kee Park, Ji Hoon Phi, Kyu-Chang Wang, Seung U. Kim, Seung-Ki Kim

Abstract

With recent advancements in stem cell-based gene therapy, concerns about safety have grown. Stem cell-based gene therapies may pose the risk of immunological problems and oncogenesis. We investigated the feasibility of treating glioblastomas with neural stem cells [(NSCs), HB1.F3 cells] expressing double prodrug enzymes [cytosine deaminase (CD) and tyrosine kinase (TK)] to eliminate the NSCs following treatment for safety purposes. First, the in vitro and in vivo therapeutic efficacies of NSCs engineered with double prodrug enzymes (HB1.F3-CD.TK cells) were compared to cells expressing a single prodrug enzyme (HB1.F3-CD). Second, the degree of safety achieved by NSC elimination was compared with an in vitro viability assay of the NSCs after treatment with the double prodrugs. We further compared the differences in in vivo proliferation of control, single prodrug enzyme and double prodrug enzyme expressing NSCs. HB1.F3-CD.TK cells showed a better or comparable treatment outcome than HB1.F3-CD cells in vitro and in vivo. For safety, HB1.F3-CD.TK cells showed the least viability in vitro after treatment with prodrugs compared to HB1.F3 and HB1.F3-CD cells. Additionally, the in vivo proliferation among the injected NSCs found in the tumor was the smallest for HB1.F3-CD.TK cells. Double-prodrug enzyme-directed gene therapy shows good therapeutic efficacy as well as efficient eradication of the NSCs to ensure safety for clinical applications of stem cell-based gene therapies.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 14%
Unknown 12 86%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 21%
Unspecified 2 14%
Researcher 2 14%
Student > Bachelor 2 14%
Student > Doctoral Student 2 14%
Other 3 21%
Readers by discipline Count As %
Medicine and Dentistry 6 43%
Agricultural and Biological Sciences 4 29%
Unspecified 2 14%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Chemical Engineering 1 7%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 October 2013.
All research outputs
#10,914,909
of 12,317,289 outputs
Outputs from Journal of Neuro-Oncology
#1,444
of 1,806 outputs
Outputs of similar age
#141,005
of 168,119 outputs
Outputs of similar age from Journal of Neuro-Oncology
#27
of 38 outputs
Altmetric has tracked 12,317,289 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,806 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,119 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.